US Interleukin Inhibitors Market 2026-2035

Description

List of Tables

US Interleukin Inhibitors Market Size, Share & Trends Analysis Report by Product Type (IL-1 Inhibitors, IL-5 Inhibitors, IL-6 Inhibitors, IL-17 Inhibitors, and IL-23 Inhibitors), and by Application (Arthritis, Asthma, Eczema, Inflammatory Bowel Disease (IBD), Psoriasis, and Others), Forecast Period (2026-2035)

Industry Overview

US interleukin inhibitors market was valued at $14,680.6 million in 2025 and is projected to reach $42.141.1 million by 2035, growing at a CAGR 11.2% during the forecast period (2026-2035). The US interleukin inhibitors market is expanding steadily as pharmaceutical companies, biotechnology firms, and healthcare providers increasingly adopt targeted immunotherapies to manage chronic inflammatory and autoimmune diseases. Leading companies such as AbbVie, Amgen, and Eli Lilly are investing heavily in IL-1, IL-6, IL-17, and IL-23 inhibitors, supported by extensive clinical trials and robust R&D pipelines. Rising prevalence of conditions like rheumatoid arthritis, psoriasis, asthma, and inflammatory bowel disease, coupled with strong reimbursement frameworks and regulatory support from the FDA, is driving rapid adoption of these biologic therapies.

Market Dynamics

Rising Integration of Biologics and Targeted Therapies in Clinical Practice

The US market growth is fueled by the increasing incorporation of interleukin inhibitors into treatment protocols across hospitals, specialty clinics, and outpatient care centers. Targeted therapies are preferred due to their ability to directly modulate inflammatory pathways, reduce disease progression, and improve patient quality of life. Partnerships between pharmaceutical companies, clinical research organizations, and healthcare systems are accelerating patient access and adoption.

Focus on Innovation, Lifecycle Expansion, and Personalized Immunotherapy

Advancements in monoclonal antibody engineering, next-generation biologics, and biomarker-driven patient stratification are driving innovation in the US interleukin inhibitors market. Companies are expanding indications, improving dosing convenience, and conducting real-world evidence studies to optimize outcomes. Federal programs supporting biotechnology innovation, alongside public-private initiatives, are further accelerating the adoption of advanced immunotherapies, reinforcing the US's leadership position in the global interleukin inhibitors landscape.

Market Segmentation

Based on the product type, the market is segmented into IL-1 inhibitors, IL-5 inhibitors, IL-6 inhibitors, IL-17 inhibitors, and IL-23 inhibitors.
Based on the application, the market is segmented into arthritis, asthma, eczema, inflammatory bowel disease (IBD), psoriasis, and others.

IL-17 Inhibitors Segment to Lead the Market with the Largest Share

In the US, the IL-17 inhibitors segment is emerging as the leading driver of the interleukin inhibitors market, propelled by strong clinical adoption for chronic inflammatory conditions such as psoriasis, psoriatic arthritis, and ankylosing spondylitis. These therapies are widely preferred due to their targeted mechanism of action, rapid symptom relief, and durable long-term efficacy. High physician awareness, early adoption of advanced biologics, and streamlined regulatory pathways through the FDA reinforce the leadership of IL-17 inhibitors in the US market. Ongoing product innovations, expansion into additional indications, and lifecycle management strategies further strengthen this segment's dominant market share, making IL-17 inhibitors a cornerstone of US immunology treatment.

Arthritis: A Key Segment in US Market Growth

Arthritis is a critical application segment in the US interleukin inhibitors market, driven by the high prevalence of rheumatoid arthritis and other inflammatory joint disorders. IL-6 and IL-17 inhibitors are increasingly integrated into clinical guidelines for patients with moderate to severe disease who show inadequate response to conventional DMARDs. The segment's growth is supported by strong reimbursement policies, widespread access to specialty care, and robust clinical evidence demonstrating long-term efficacy and improved patient quality of life across the country.

Market Players Outlook

The major companies operating in the US interleukin inhibitors market include AbbVie Inc., Amgen Inc., Eli Lilly and Company, Johnson & Johnson Services, Inc., Novartis AG, among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Development

In September 2025, AbbVie Inc. announced the initiation of a Phase III clinical trial for an expanded indication of its IL-23 inhibitor targeting ulcerative colitis and Crohn's disease. This expansion reflects the company's strategy to broaden therapeutic reach and reinforce its leadership in interleukin-targeted therapies in the US.
In July 2025, Amgen Inc. launched a real-world evidence study program to evaluate the long-term efficacy and safety of its IL-6 and IL-17 inhibitors in patients with moderate to severe rheumatoid arthritis. The initiative aims to support label expansion and optimize clinical treatment guidelines across the US.

The Report Covers:

Market value data analysis of 2025 and forecast to 2035.
Annualized market revenues ($ million) for each market segment.
Country-wise analysis of major geographical regions.
Key companies operating in the US interleukin inhibitors market.
Based on the availability of data, information related to new products and relevant news is also available in the report.
Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
Analysis of market-entry and market expansion strategies.
Competitive strategies by identifying 'who-stands-where' in the market.

Product Code: OMR2023422

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
US Interleukin Inhibitors Market Sales Analysis - Product Type | Application ($ Million)
1.1. Research Methodology
Primary Research Approach
Secondary Research Approach
1.2. Market Snapshot

2. Market Overview and Insights

2.1. Scope of the Study
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Interleukin Inhibitors Industry Trends
- 2.2.2. Market Recommendations

3. Market Determinants

3.1. Market Drivers
- 3.1.1. Drivers For US Interleukin Inhibitors Market: Impact Analysis
3.2. Market Pain Points and Challenges
- 3.2.1. Restraints For US Interleukin Inhibitors Market: Impact Analysis
3.3. Market Opportunities
- 3.3.1. Opportunities For US Interleukin Inhibitors Market: Impact Analysis

4. Competitive Landscape

4.1. Competitive Dashboard - US Interleukin Inhibitors Market Revenue and Share by Manufacturers
Interleukin Inhibitors Product Comparison Analysis
4.2. Key Company Analysis
- 4.2.1. AbbVie Inc.
  - 4.2.1.1. Overview
  - 4.2.1.2. Product Portfolio
  - 4.2.1.3. Financial Analysis
  - 4.2.1.4. SWOT Analysis
  - 4.2.1.5. Business Strategy
- 4.2.2. Amgen Inc.
  - 4.2.2.1. Overview
  - 4.2.2.2. Product Portfolio
  - 4.2.2.3. Financial Analysis
  - 4.2.2.4. SWOT Analysis
  - 4.2.2.5. Business Strategy
- 4.2.3. Eli Lilly and Company
  - 4.2.3.1. Overview
  - 4.2.3.2. Product Portfolio
  - 4.2.3.3. Financial Analysis
  - 4.2.3.4. SWOT Analysis
  - 4.2.3.5. Business Strategy
- 4.2.4. Johnson & Johnson Services, Inc.
  - 4.2.4.1. Overview
  - 4.2.4.2. Product Portfolio
  - 4.2.4.3. Financial Analysis
  - 4.2.4.4. SWOT Analysis
  - 4.2.4.5. Business Strategy
- 4.2.5. Novartis AG
  - 4.2.5.1. Overview
  - 4.2.5.2. Product Portfolio
  - 4.2.5.3. Financial Analysis
  - 4.2.5.4. SWOT Analysis
  - 4.2.5.5. Business Strategy
4.3. Top Winning Strategies by Market Players
- 4.3.1. Merger and Acquisition
- 4.3.2. Product Launch
- 4.3.3. Partnership And Collaboration

5. US Interleukin Inhibitors Market Sales Analysis by Product Type ($ Million)

5.1. IL-1 Inhibitors
5.2. IL-5 Inhibitors
5.3. IL-6 Inhibitors
5.4. IL-17 Inhibitors
5.5. IL-23 Inhibitors

6. US Interleukin Inhibitors Market Sales Analysis by Application ($ Million)

6.1. Arthritis
6.2. Asthma
6.3. Eczema
6.4. Inflammatory Bowel Disease (IBD)
6.5. Psoriasis
6.6. Others

7. Company Profiles

7.1. AbbVie Inc.
- 7.1.1. Quick Facts
- 7.1.2. Company Overview
- 7.1.3. Product Portfolio
- 7.1.4. Business Strategies
7.2. Amgen Inc.
- 7.2.1. Quick Facts
- 7.2.2. Company Overview
- 7.2.3. Product Portfolio
- 7.2.4. Business Strategies
7.3. AstraZeneca PLC
- 7.3.1. Quick Facts
- 7.3.2. Company Overview
- 7.3.3. Product Portfolio
- 7.3.4. Business Strategies
7.4. Bausch Health Companies Inc.
- 7.4.1. Quick Facts
- 7.4.2. Company Overview
- 7.4.3. Product Portfolio
- 7.4.4. Business Strategies
7.5. Bayer AG
- 7.5.1. Quick Facts
- 7.5.2. Company Overview
- 7.5.3. Product Portfolio
- 7.5.4. Business Strategies
7.6. Boehringer Ingelheim International GmbH
- 7.6.1. Quick Facts
- 7.6.2. Company Overview
- 7.6.3. Product Portfolio
- 7.6.4. Business Strategies
7.7. Bristol-Myers Squibb Company
- 7.7.1. Quick Facts
- 7.7.2. Company Overview
- 7.7.3. Product Portfolio
- 7.7.4. Business Strategies
7.8. Eli Lilly and Company
- 7.8.1. Quick Facts
- 7.8.2. Company Overview
- 7.8.3. Product Portfolio
- 7.8.4. Business Strategies
7.9. F. Hoffmann-La Roche Ltd
- 7.9.1. Quick Facts
- 7.9.2. Company Overview
- 7.9.3. Product Portfolio
- 7.9.4. Business Strategies
7.10. GlaxoSmithKline plc
- 7.10.1. Quick Facts
- 7.10.2. Company Overview
- 7.10.3. Product Portfolio
- 7.10.4. Business Strategies
7.11. Johnson & Johnson Services, Inc.
- 7.11.1. Quick Facts
- 7.11.2. Company Overview
- 7.11.3. Product Portfolio
- 7.11.4. Business Strategies
7.12. Merck & Co., Inc.
- 7.12.1. Quick Facts
- 7.12.2. Company Overview
- 7.12.3. Product Portfolio
- 7.12.4. Business Strategies
7.13. Novartis AG
- 7.13.1. Quick Facts
- 7.13.2. Company Overview
- 7.13.3. Product Portfolio
- 7.13.4. Business Strategies
7.14. Pfizer Inc.
- 7.14.1. Quick Facts
- 7.14.2. Company Overview
- 7.14.3. Product Portfolio
- 7.14.4. Business Strategies
7.15. Regeneron Pharmaceuticals, Inc.
- 7.15.1. Quick Facts
- 7.15.2. Company Overview
- 7.15.3. Product Portfolio
- 7.15.4. Business Strategies
7.16. Sanofi S.A.
- 7.16.1. Quick Facts
- 7.16.2. Company Overview
- 7.16.3. Product Portfolio
- 7.16.4. Business Strategies
7.17. Sun Pharmaceutical Industries Limited
- 7.17.1. Quick Facts
- 7.17.2. Company Overview
- 7.17.3. Product Portfolio
- 7.17.4. Business Strategies
7.18. Takeda Pharmaceutical Company Limited
- 7.18.1. Quick Facts
- 7.18.2. Company Overview
- 7.18.3. Product Portfolio
- 7.18.4. Business Strategies
7.19. Teva Pharmaceutical Industries Ltd.
- 7.19.1. Quick Facts
- 7.19.2. Company Overview
- 7.19.3. Product Portfolio
- 7.19.4. Business Strategies
7.20. UCB S.A.
- 7.20.1. Quick Facts
- 7.20.2. Company Overview
- 7.20.3. Product Portfolio
- 7.20.4. Business Strategies